83 results about "Allergic asthma" patented technology

Methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate-to-severe asthma, persistent asthma or the like) and associated conditions (e.g., ABPA, ABPA comorbid with asthma, ABPA comorbid with cystic fibrosis (CF), ABPA comorbid with asthma and CF) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The invention discloses an application of pinoresin-4-O-glucoside in preparation of a medicine for treating allergic asthma diseases, and according to the application provided by the invention, the pinoresin-4-O-glucoside can inhibit expression and activity of induced nitric oxide synthase, remarkably improve airway hyperresponsiveness, relieve lung inflammation and relieve expression of asthma related indexes, and can be used for treating allergic asthma diseases. The application has a prospect of developing a novel anti-asthma medicine.

The invention discloses a child allergic asthma marker and application thereof, and belongs to the technical field of biological medicine. Through detection of clinical samples, compared with healthy control children, the blood plasma BCAA level of children with allergic asthma is remarkably increased, and the kit has good diagnostic value. After medication treatment, the blood plasma BCAA level of children with allergic asthma is obviously reduced, and the composition has a good treatment and prognosis value. Therefore, the plasma BCAA can be used as a marker for diagnosis and prognosis of the children allergic asthma, and a foundation is laid for guiding clinical medication.

The invention relates to the technical field of medicines, in particular to medical application of a kedilao extract. The invention discloses the medical application of the kedilao extract for preventing, relieving and / or treating allergic asthma for the first time. The kedilao extract can reduce inflammatory cell infiltration, improve airway structure damage and improve airway wall thickening; the secretion of Th1 type cytokines is improved, the secretion of Th2 type cytokines is reduced, and the effect of obviously relieving asthma is achieved. Compared with an existing medicine for treating asthma, the kedilao extract is safer, more effective, milder and lasting, the action mechanism is multi-target and multi-effect, and the situation that a single-target medicine generates strong drug resistance is avoided. Therefore, the kdilao extract has considerable development and utilization values in the aspect of relieving and treating the allergic asthma.

The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) NO.30979, the preservation date is June 17, 2024, the preservation classification is named as Lactobacillus brevis, and the preservation unit is the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms. The strain is harmless to animals and has the remarkable effects of relieving lung tissue inflammatory infiltration caused by bronchial asthma, reducing release of serum IgE and Th2 type cell factors, inhibiting activation of an NF-kappa B channel and improving allergic airway inflammation. The invention also discloses application of the strain and the thallus component thereof in preparation of drugs for preventing and treating allergic asthma.

A preparation method of the triterpenoid A2 comprises the following steps: drying and crushing the oriental oriental waterplantain rhizome, dipping the oriental oriental waterplantain rhizome in acetone at room temperature, crushing and extracting, filtering, merging filtrate, and concentrating under reduced pressure to obtain an extract; sequentially extracting the extract with petroleum ether, dichloromethane, ethyl acetate and n-butyl alcohol with the same amount, concentrating and drying to obtain a petroleum ether part, a dichloromethane part, an ethyl acetate part, an n-butyl alcohol part and a water part; dissolving the dichloromethane part with methanol, stirring silica gel, packing and eluting for four times to obtain a target fraction; and loading the target fractions on a chromatographic column, collecting fractions within the retention time, concentrating and drying to obtain the target fractions. The raw materials are rich, a unique preparation method is adopted, and the compound A2 can improve airway inflammation and airway hyperresponsiveness of OVA-induced allergic asthma, can be used for preparing drugs for treating allergic asthma, develops the medicinal value and economic value of oriental rhizoma alismatis, and has huge economic and social benefits.

The present invention provides a method for establishing a subcutaneous specific immunotherapy model of Alternaria allergic asthma mice using Alt a 1. The method comprises S1, using Alternaria crude extract (Alternaria) to perform nasal drops for sensitization and stimulation of mice; S2, using Alternaria, rAlt a 1 or nAlt a 1 protein to perform SCIT on the sensitized and stimulated mice respectively; S3, using Alternaria again to perform nasal drops for stimulation of the mice that have received SCIT. The method has a simple operation method, a moderate modeling time, a good model effect, and high repeatability, and is expected to be further promoted and used.

The invention relates to a preparation method and application of an effective part of hyssop officinalis L. The method comprises the following steps: taking hyssop officinalis L., cutting into cun sections, carrying out reflux extraction with ethanol, filtering, merging filtrates, carrying out vacuum concentration, and carrying out vacuum drying to obtain a hyssop officinalis L. ethanol extract; and dissolving the extract in ethanol, extracting with ethyl acetate, concentrating the upper layer under reduced pressure, and drying in vacuum to obtain the effective part of hyssop officinalis. The invention further discloses application of the effective part of the hyssop officinalis obtained through testing in preparation of the anti-allergic asthma medicine.

The invention discloses a traditional Chinese medicine composition for treating allergic asthma and a preparation method thereof, and the traditional Chinese medicine composition comprises the following components in parts by weight: 2-10 parts of honey-fried ephedra, 3-10 parts of scutellaria baicalensis, 9-15 parts of momordica grosvenori, 9-15 parts of rhizoma dioscoreae nipponicae, 5-10 parts of scalded semen armeniacae amarae, 2-10 parts of liquorice, 3-10 parts of fried fructus perillae, 3-9 parts of fried semen brassicae, 5-10 parts of schizonepeta, 3-10 parts of platycodon grandiflorum and 5-12 parts of fried semen raphani. The pharmaceutical composition disclosed by the invention is a pure traditional Chinese medicine preparation, and can be used for reducing the level of eosinophilic granulocytes, increasing the number of alveolar macrophages and effectively improving abnormal immune response in an asthma process; lesion degrees such as lung tissue inflammatory cell infiltration, alveolar wall edema and goblet cell hyperplasia are relieved; secretion of Th2 type inflammatory cell related factors and IgE is reduced, and finally the effect of treating allergic asthma inflammatory response is achieved.

The invention belongs to the technical field of medicine, and discloses an artemisia annua pollen allergen sublingual drop as well as a preparation process and application thereof.The preparation is realized through the following core processes: firstly, performing raw material screening and supercritical CO2 degreasing pretreatment on artemisia annua pollen at the full-bloom stage in North China, then performing graded ultralow-temperature freezing and crushing, and performing freeze drying to obtain the artemisia annua pollen allergen sublingual drop. The particle size D90 of the superfine powder is smaller than or equal to 4 microns; then adopting a neutral protease and pectinase composite enzymatic hydrolysis system, and combining 4 DEG C low-temperature pulse ultrasound-assisted treatment to accelerate the dissolution of allergens; carrying out tangential flow grading purification and buffer solution replacement by virtue of 100kDa and 5kDa PES (Polyether Sulfonate) ultrafiltration membranes, and introducing a compound stabilizer; and finally, performing three-stage sterile filtration, and performing encapsulation and preservation. According to the process, through multi-link collaborative optimization, the extraction efficiency and activity stability of allergens are improved, and the prepared sublingual drops have the effects of improving allergic rhinitis, allergic asthma and airway inflammation and also have excellent permeability.

The invention discloses an application of glucopyranose galactooligosacharide in preparation of a medicine for treating and / or preventing allergic asthma. The invention finds that the glucopyranose galactooligosaccharide can obviously relieve airway inflammatory reaction of an allergen-induced allergic asthma model, including reducing airway inflammatory factor level, improving airway hyperreactivity and reducing lung inflammatory cell infiltration, and has no abnormal influence on blood routine and main organ functions; the composition has the advantages of small drug application dosage, low pharmaceutical cost, high safety, remarkable drug effect and the like, and has a wide application prospect.

To provide methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate-to-severe asthma, persistent asthma or the like) and associated conditions (e.g., ABPA, ABPA comorbid with asthma, ABPA comorbid with cystic fibrosis (CF), ABPA comorbid with asthma and CF) in a subject.SOLUTION: The present invention provides methods comprising the step of administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.SELECTED DRAWING: None

The invention relates to a gene therapy vector nucleic acid construct for allergic diseases and a use method of the gene therapy vector nucleic acid construct. In particular to an expression cassette, the expression cassette comprises the following elements: a promoter, an optional first signal peptide coding sequence, a heavy chain coding sequence of an anti-IgE antibody, an optional linker sequence, an optional second signal peptide coding sequence and a light chain coding sequence of the anti-IgE antibody, and the invention also provides an adeno-associated virus vector containing the expression cassette. The gene expression framework of the adeno-associated virus vector can realize high-level expression of a target gene, and can be used for treating allergic diseases such as allergic asthma and chronic spontaneous urticaria.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

The invention relates to the technical field of probiotics, in particular to an application of a probiotic (Bifidobacterium longum) in allergic asthma (preventing, relieving or treating allergic asthma). The invention relates to an application of probiotics in allergic asthma, in particular to an application of the probiotics in inhibiting a PI3K / AKT / NF-kappa B signal channel. According to the probiotics disclosed by the invention, activation of a PI3K / AKT / NF-kappa B signal channel is specifically inhibited, immune imbalance is regulated and controlled from the source, and Th2 type immune response is effectively inhibited. Specifically, the total IgE level in serum and the expression of Th2 type cytokines such as IL-4, IL-5 and IL-13 are remarkably reduced, the inflammatory response of the airway mainly caused by eosinophilic granulocyte infiltration is relieved, and the airway high reactivity and airway remodeling are effectively improved. The invention provides a novel intervention strategy which is clear in mechanism, high in safety and capable of treating both symptoms and root causes according to the intestine-lung axis theory, and has a wide application prospect in the aspect of treating allergic asthma.

150mg / mL omalizumab formulation for use in a method of treatment of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, wherein the omalizumab is administered subcutaneously by a syringe.

The present invention provides an antibody comprising citrulline epitope or a binding fragment thereof for use in the treatment or prevention of a disease associated with release of an extracellular trap from a cell, such as a neutrophil extracellular trap (NET)-associated disease (NET-associated disease) or an eosinophil extracellular trap (EET)-associated disease (EET-associated disease), the method comprises administering at least one dose of an antibody at a specific concentration. The present invention also provides these methods themselves. NET related diseases include systemic lupus erythematosus (SLE), lupus, septicemia, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, and the like. Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulogenic uveitis, granulogenic uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The invention also provides a pharmaceutical composition and a method for treating or preventing NET related diseases. Such as SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, Parkinson's disease, Lewy body dementia, asthma, and the like. Allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulometric uveitis, granulometric uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The EET-related diseases include eosinophilic granulocyte diseases or conditions, such as eosinophilic granulocyte diseases or conditions of skin; a respiratory eosinophilic granulocyte disease or condition; gastrointestinal eosinophilic cell diseases or disorders; allergic diseases or conditions; or worm, fungus, virus or bacterial infection.

The present application relates to the field of chemical drugs, and discloses a P2X7 receptor antagonist. The structure of the P2X7 receptor antagonist is as shown in formula I. The present application has found that the compound shown in formula I not only has excellent antagonistic activity for the P2X7 receptor, but also has excellent metabolic stability and pharmacokinetic properties. Compared with the positive control JNJ47965567, the metabolic stability and pharmacokinetic properties of the compound of the present application are significantly improved, and the druggability is significantly better. The compound shown in formula I is used as a P2X7 receptor antagonist, and can be used to prepare a drug for treating illnesses such as inflammation and inflammation-related diseases, kidney diseases, respiratory diseases, cancer, pain, central nervous system diseases, radiation-induced brain injury, cerebral ischemia, myocardial injury, diabetes, depression, lupus erythematosus, atherosclerosis, and allergic asthma, and has broad application prospects.

The application provides a drug delivery system and a preparation method and application thereof, and relates to the technical field of biomedicine.The drug delivery system comprises mesenchymal stem cell exosomes, black phosphorus quantum dots and budesonide.The drug delivery system contains mesenchymal stem cell exosomes, has the functions of immune regulation, anti-inflammation and lung targeting, realizes lung targeted delivery of the black phosphorus quantum dots loaded with budesonide, and realizes precise regulation of lung temperature by utilizing the near-infrared photothermal effect of the black phosphorus quantum dots in asthma for the first time, so that local hyperthermia for allergic asthma is realized.The drug delivery system utilizes the photothermal effect of the black phosphorus quantum dots in the carrier to control the release speed of budesonide, is beneficial to maintaining the optimal drug concentration in the lung, and is expected to reduce the dosage and frequency of medication and reduce the risk of side effects.The application firstly cooperates the mesenchymal stem cell exosomes, local hyperthermia and the immune regulation effect of budesonide for the treatment of allergic asthma.

Provided herein are method for diagnosis and treatment of severe and moderate allergic asthma using skin surface biomarkers.

The invention discloses application of an inhibitor Acevaltrate targeting PCBP2 in preparation of a medicine for treating allergic asthma, and belongs to the technical field of biological medicine. The invention discloses application of PCBP2 as a molecular target of a drug for treating allergic asthma. The core pathological mechanism of allergic asthma is closely related to M2 polarization of macrophages, and PCBP2 positively drives the polarization process by regulating an STAT6 signal channel. Acevaltrate can specifically inhibit the biological function of PCBP2 and block M2 polarization of macrophages induced by IL-4 / IL-13, so that airway inflammation is relieved, over-generation of IgE (immunoglobulin E) is inhibited, and airway remodeling is improved. The invention further provides a pharmaceutical composition containing the Acevaltrate, a drug combination scheme of the Acevaltrate and an existing asthma treatment drug, and a drug screening system based on a PCBP2-M2 polarization axis. The technology breaks through the limitation of an existing asthma treatment target spot, realizes the trans-boundary application of Acevaltrate from an anti-tumor drug to an anti-asthma drug, provides an accurate and efficient novel treatment strategy for allergic asthma, especially refractory asthma, and has remarkable clinical transformation value and wide application prospects.

The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and / or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.

The present invention relates to a system and method for providing a deterioration risk score for a patient's respiratory disease. The system measures the patient's cardiac signal and / or blood circulation signal, and detects cough events and sneeze events in the measured data. Cough events and sneeze events indicate the onset of an infectious disease and / or allergy that may rapidly exacerbate the patient's respiratory disease. Accordingly, the system is configured to unobtrusively provide a deterioration risk score to the patient and / or the doctor.

A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg / mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.

This invention belongs to the field of respiratory disease drugs and fermentation engineering technology, specifically relating to a traditional Chinese medicine composition for improving allergic asthma and its preparation method. The traditional Chinese medicine composition for improving allergic asthma comprises the following components in parts by weight: Ephedra 10-20 parts, Earthworm 1-10 parts, Mulberry Bark 3-17 parts, Poria 6-17 parts, Schisandra Fruit 4-15 parts, Cinnamon Twig 8-18 parts, and Perilla Leaf 1-10 parts. This invention, through screening various high-quality traditional Chinese medicinal materials and rationally combining them, forms a traditional Chinese medicine composition with synergistic effects. This composition is refined through a specific preparation process, effectively preserving the active ingredients in the medicinal materials, and exhibits significant effects in treating and improving allergic asthma. This invention also has advantages such as high safety, few side effects, and suitability for long-term use.

The invention provides a traditional Chinese medicine extract for treating bronchial asthma and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine extraction. The preparation method comprises the following steps: soaking rhizoma belamcandae, schisandra chinensis, ginger, jujube and ephedra with water, decocting with water, extracting, soaking ephedra independently, adding rhizoma belamcandae, schisandra chinensis, ginger and jujube, decocting together, and filtering to obtain a total water extract; soaking aster tataricus, tussilago farfara and rhizoma pinellinae praeparata with an ethanol aqueous solution, and performing percolation extraction to obtain a percolate; mixing the total water extract and the percolation liquid, and concentrating to obtain an extract; and soaking the herba asari with water, performing distillation extraction to obtain volatile oil, and mixing the extract and the volatile oil to obtain the rhizoma belamcandae and herba ephedrae decoction extract. The blackberry lily and ephedra decoction extract provided by the invention can remarkably improve release of inflammatory factors and airway remodeling factors related to allergic asthma in an airway, delay airway remodeling, regulate immune balance and inhibit pathological conditions such as overexpression of mucoprotein and inflammatory protein.

OF THE INVENTION LOCAL ADMINISTRATION OF RIPK2 INHIBITORS FOR THE CURATIVE TREATMENT OF ALLERGIC ASTHMA The present invention relates to a method for use in the treatment of Asthma. Here, the inventors identified the receptor-interacting serine / threonione protein kinas 2 (RIPK2) as a novel therapeutic target to improve Asthma-related diseases. They demonstrated that a local preventive administration of the RIPK2 inhibitor reduced AHR, airway eosinophilia, mucus production, Th2 cytokines and the alarmin IL-33. Moreover, they demonstrated the early role of IL-33 in the NOD1-dependent response of the epithelium to HDM. Therefore, the inventors demonstrated that the local interference of the NOD1 signaling pathway through RIPK2 inhibition may represent a new therapeutic approach in asthma. Other pulmonary diseases could also benefit of this treatment. Thus, the present invention relates to a method for use in the curative treatment of HDM-induced asthma comprising administrating to a subject in need thereof a therapeutically effective amount of an inhibitor of RIPK2.

The invention relates to the technical field of medicines, in particular to a pharmaceutical composition and application thereof in preparation of drugs for preventing or treating allergic asthma. The invention relates to a pharmaceutical composition which is definite in active ingredient, high in safety and capable of efficiently treating allergic asthma through a multi-target synergistic effect. The pharmaceutical composition comprises 8-O-debenzoyl paeoniflorin (8-DPF), pentagalloylglucose (PGG), paeoniflorin (PF) and white paeony root crude polysaccharide which serve as active ingredients. According to the composition, through scientific compatibility of the active ingredients of PGG, PF and 8-DPF and the radix paeoniae alba crude polysaccharide, triple effects of anti-inflammation, immunoregulation and bronchial relaxation are achieved, and the problems that an existing medicine is single in target spot, large in side effect, low in bioavailability and the like are solved.

150mg / mL omalizumab formulation for use in a method of treatment of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, wherein the omalizumab is administered subcutaneously by a syringe.

This invention discloses a fusion peptide with synergistic anti-allergic effects, an anti-LTB4 monoclonal antibody, and an anti-allergic drug composition thereof. The fusion peptide is composed of peptide A, which inhibits histamine release, and peptide B, which blocks mast cell activation signals, covalently linked by a linker peptide, which can synergistically inhibit mast cell activation. The anti-LTB4 monoclonal antibody can specifically bind to LTB4, blocking its mediated inflammatory response. Combining the fusion peptide, the anti-LTB4 monoclonal antibody, and myricetin, which has antioxidant activity, forms a multi-target drug composition that can synergistically inhibit allergic reactions from multiple aspects, such as inhibiting mast cell degranulation, blocking the action of inflammatory mediators, and clearing oxidative stress products. In vitro cell experiments and OVA-induced allergic asthma mouse models have demonstrated that the anti-allergic effect of this composition is significantly better than that of a single component, and it has no obvious toxicity, providing a new candidate drug for the efficient treatment of allergic diseases.